Gotham Therapeutics and Mercachem Announce Progress in Compound Library Development Tailored for Epitranscriptomic Drug Discovery
- Category: More News
- Published on Wednesday, 17 July 2019 09:14
- Hits: 663
Research led to a collection of over 2,000 analogues and over 80 distinct chemotypes displaying an up to 1,000-fold increased affinity to epitranscriptomic targets
NEW YORK, NY, USA & NIJMEGEN, The Netherlands I July 17, 2019 I Gotham Therapeutics, a biotechnology company developing a novel drug class targeting RNA-modifying proteins, and Mercachem, the leading European contract research organization, today announced the generation of a high-quality compound library tailor-made for accelerated hit generation and hit-to-lead expansion against large parts of the epitranscriptomic target space. Using this library will further accelerate Gotham’s drug discovery efforts as the company expands its epitranscriptomics pipeline beyond the current lead program targeting the METTL3/METTL14 complex.
“Together with Mercachem, we have developed a unique approach to identify small-molecule master keys that are able to unlock novel targets and address the specific pharmacophoric features this target family shares,” said Dr. Gerhard Müller, Chief Scientific Officer of Gotham Therapeutics. “This targeted library further strengthens our drug discovery engine and will be repeatedly explored as we continue our collaboration with Mercachem in all future pipeline projects along the hit-to-lead candidate trajectory.”
“The growing epitranscriptomic-directed compound collection will enable Gotham to more rapidly advance drug discovery projects against novel targets,” said Dr. Frank Leemhuis, Managing Director of Mercachem. “We look forward to seeing the progress Gotham aims to make in the epitranscriptomic space with the assets and knowhow gleaned as part of our collaboration.”
As a result of the collaboration, over 2,000 analogues and over 80 distinct chemotypes have been produced, which clearly comprise several privileged structures for binding to epitranscriptomic targets, demonstrating and utilizing cross-target synergies within this target space. The consistent utilization of structure-based drug design combined with the excellence in scaffold design and library chemistry converged to yield several molecules with up to a thousand-fold increased affinity for some of the targets.
About Gotham Therapeutics:
Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting RNA-modifying proteins. By changing the activity of proteins that modify messenger RNA, we aim to develop new treatment options for patients suffering from cancers, auto-immune and neurodegenerative diseases. We are applying a 360-degree approach to small molecule drug design to build a pipeline based on the promise of this rapidly emerging biopharmaceutical field. For more information, please visit: www.gothamtx.com
About Mercachem and MercachemSyncom:
Mercachem is part of MercachemSyncom, the leading European contract research organization offering innovative chemistry, medicinal chemistry and early process research services, and GMP production to accelerate the drug discovery and development process in a flexible and cost-effective way. MercachemSyncom offers integrated drug discovery services from hit to clinic. Working for many pharmaceutical and biotech companies throughout the world, MercachemSyncom is recognized for its high-quality products and services and its unprecedented problem-solving capabilities. More information on Mercachem can be found on the company website, www.mercachem.com.
SOURCE: Gotham Therapeutics